🇺🇸 Y-90 Ibritumomab tiuxetan in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 3
Most-reported reactions
- Gastrointestinal Toxicity — 1 report (33.33%)
- Lymphopenia — 1 report (33.33%)
- Pulmonary Toxicity — 1 report (33.33%)
Frequently asked questions
Is Y-90 Ibritumomab tiuxetan approved in United States?
Y-90 Ibritumomab tiuxetan does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Y-90 Ibritumomab tiuxetan in United States?
CABYC is the originator. The local marketing authorisation holder may differ — check the official source linked above.